Stray Dog

Palantir wins Changshin but loses Westpac

  • Good news: Korean footwear maker Changshin signed up for Foundry and AIP, following the same bootcamp, pilot and expansion funnel.
  • Bad news: Westpac is not renewing, the first time reputational pressure has reached a large private-sector customer.
  • Bad news: NHS England asked Palantir to submit claims about results for review before publication, so renewal odds keep falling.
Read the full notes

The Korean Changshin deal continues the bootcamp, pilot and expansion funnel, and shows the ontology layer can be repeated in discrete manufacturing. Westpac's non-renewal is the first time reputational pressure has reached a large private-sector customer. The way NHS results are presented has been challenged, so the odds of renewal keep falling.

Read more

After the US midterms, the risk of scrutiny over ICE contracts and the ethics of military AI is higher, though Maven itself is likely to continue.

Key evidence

  • Korean footwear contract manufacturer Changshin has signed up for Foundry and AIP. It has about 80,000 employees worldwide, factories in Vietnam, China and Indonesia, and cumulative output of 1 billion pairs. The deal covers the whole process, from shoe development and sampling plans to factory production.
  • It follows the AgentCamp (agent bootcamp), then runs initial workflows on real data, then moves to the next stage. This is the same funnel as Hyundai Heavy Industries on 2 Nov, and the sportswear brand on the earnings call that went from $1.6 million to $21 million.
  • The Changshin deal is an announced partnership. The value and duration have not been disclosed.
  • Australia's Westpac is not renewing (first reported by Capital Brief, followed up by Green Left on 5 Nov). The official reason is technology simplification. The campaigners say it was the result of pressure from the Dump Palantir coalition of more than 40 organisations.
  • Australian supermarket chain Coles cut ties two months ago. International commercial revenue rose only 1% quarter on quarter in Q3, and customer losses abroad from reputational pressure have spread to large private-sector customers.
  • NHS England has asked Palantir to submit claims about the platform's results to it for review before publication (HSJ 3-4 Nov, Guardian/Medact, Resultsense 4 Nov). This followed concerns raised by the statistics regulator.
Show 6 more
  • A Medact freedom of information request found that, of the 137 trusts NHS England lists as having seen results, 29 said the platform was of no use or they used only a few features. The most widely deployed single clinical product, the operating theatre module, covers only 40 trusts, and Cancer 360 covers only 5.
  • There is a key timing mismatch: the independent evaluation's final report is not due until April 2029, while the decision point on breaking or renewing the contract falls in early 2027. The NHS contract has a seven-year ceiling of £330 million.
  • After the US midterms the Democrats lead in Congress (counting continues). The risk is whether the new Congress will demand release of the Department of Defense's internal investigation into the Minab school bombing.
  • The Maven Smart System has been designated a formal programme of record by memo. NATO's version of Maven reached full technical operating capability in June 2026, and Japan's Self-Defense Forces are reportedly willing to deploy it.
  • At a Bloomberg event, Mosley, head of Europe, said the company is criticised in the US for supporting Ukraine and in Europe for supporting Israel.
  • EDGAR: no new Form 4 since 30 Oct.

Catalysts to watch

  • Whether the Changshin pilot can scale to tens of millions of dollars
  • Whether more European and Australian commercial customers follow Westpac in not renewing
  • The outcome of the mismatch between the NHS independent evaluation's final report (April 2029) and the renewal decision point (early 2027)
  • Whether the new Congress demands release of the investigation into the Minab school bombing
  • Progress of political scrutiny of ICE contracts

Risks

  • Westpac is small in revenue terms, but the symbolism is large, and the coalition applying reputational pressure is spreading
  • The odds of NHS renewal keep falling. The annualised value of the £330 million seven-year ceiling is small, so the damage is to reputation more than to revenue
  • Risk from ICE contracts and ethics investigations into military AI
  • Political risk comes from both sides at once: criticism in the US over Ukraine and in Europe over Israel

Sources 5

  1. Business Wire official press release, 4 Nov (Changshin)
  2. Capital Brief first report and Green Left, 5 Nov (Westpac)
  3. HSJ 3-4 Nov, Guardian/Medact, Resultsense 4 Nov (NHS)
  4. Defense Security Monitor, 4 Nov (political exposure after the midterms)
  5. Bloomberg event (Mosley's remarks)